Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 March 1999

Urokinase plasminogen activator (u-PA) versus selected parameters of fibrinolysis in the blood of patients with renal carcinoma

Izabela Iwan-Ziętek, Zbigniew Ziętek

Med Sci Monit 1999; 5(2): CR233-238 :: ID: 505093


The process of fibrinolysis was investigated in 100 patients with renal carcinoma, on the basis of the concentration of urokinase plasminogen activator (uPA), the level of plasmin/antiplasmin complexes (complexes PAP) and the concentration of α2,-antiplasmin (α2,-AP). Additionally, euglobulin lysis time (ELT), the level of fibrin and fibrinogen degradation products (FDP) and the concentration of fibrinogen were determined. Mean concentration of antigen and activity of uPA was much higher in patients with renal carcinoma than in subjects from control group. Likewise, the level of PAP complexes was higher, while there were no significant differences in the activity of α2,-AP. Euglobulin lysis time was shorter in patients with renal carcinoma. The level of FDP was also higher while the concentration of fibrinogen did not differ significantly when compared with control group. Shorter ELT time in patients with renal cancer is the evidence for greater activation of fibrinolysis. Elevated level of PAP complexes reflects increased plasmin generation through the conversion from plasminogen as a result of higher concentrations of urokinase plasminogen activator. Increased FDP level in patients with renal carcinoma is the result of higher fibrin degradation by generated plasmin. Normal level of α2,-AP in patients with renal carcinoma is the evidence for the efficiency of mechanisms controlling fibrinolysis activation, which prevent from the development of haemorrhagic diathesis in the course of uncontrolled activation of fibrinolysis. Investigated parameters of fibrinolysis were analysed depending on the advancement of renal carcinoma. It was demonstrated that the concentration of antigen and activity of uPA, as well as the level of PAP complexes increases along with the advancement of neoplasm. This proves that the advancement of renal cancer and the increase of its mass are accompanied by stronger activation of fibrinolysis caused by increased uPA release from neoplastic cells and the endothelium of pathological vessels. The results obtained indicate that the increase of uPA level is responsible for the elevation of fibrinolytic activity in the plasma of patients with renal carcinoma. uPA comes from neoplastic cells and the endothelium of pathological vessels. Increased fibrinolytic activity carries the risk of the development of haemorrhagic diathesis.

Keywords: renal carcinoma, urokinase plasminogen activator, Fibrinolysis

Add Comment 0 Comments


01 June 2024 : Editorial  

Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals

Dinah V. Parums

DOI: 10.12659/MSM.945315

Med Sci Monit 2024; 30:e945315


In Press

Clinical Research  

Trust and Support for Cancer Research Biobanks: Insights from Cancer Patients in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.944263  

Clinical Research  

Morphological and Dimensional Analysis of the Nasopalatine Canal: Insights from Cone-Beam Computed Tomograp...

Med Sci Monit In Press; DOI: 10.12659/MSM.944424  

Clinical Research  

Hemorrhagic Cysts in the Pancreas: Risk Factors, Treatment, and Outcomes – Insights from a Single-Center Study

Med Sci Monit In Press; DOI: 10.12659/MSM.941955  

Clinical Research  

Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Managem...

Med Sci Monit In Press; DOI: 10.12659/MSM.944063  

Most Viewed Current Articles

14 Dec 2022 : Clinical Research   1,421,178

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990


17 Jan 2024 : Review article   1,355,487

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799


16 May 2023 : Clinical Research   690,090

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387


01 Jan 2022 : Editorial   50,113

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952


Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750